Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) and Annovis Bio (NYSE:ANVS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations.
Insider and Institutional Ownership
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 32.3% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Regulus Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regulus Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
| Annovis Bio | 0 | 1 | 5 | 1 | 3.00 |
Regulus Therapeutics presently has a consensus target price of $10.80, suggesting a potential upside of 655.24%. Annovis Bio has a consensus target price of $32.17, suggesting a potential upside of 370.27%. Given Regulus Therapeutics’ higher probable upside, equities analysts clearly believe Regulus Therapeutics is more favorable than Annovis Bio.
Profitability
This table compares Regulus Therapeutics and Annovis Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regulus Therapeutics | N/A | -53.07% | -48.58% |
| Annovis Bio | N/A | -876.22% | -311.00% |
Earnings and Valuation
This table compares Regulus Therapeutics and Annovis Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regulus Therapeutics | N/A | N/A | -$30.04 million | ($1.07) | -1.34 |
| Annovis Bio | N/A | N/A | -$56.20 million | ($4.46) | -1.53 |
Annovis Bio is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Regulus Therapeutics beats Annovis Bio on 7 of the 11 factors compared between the two stocks.
About Regulus Therapeutics
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
